![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pharmacokinetic interactions of darunavir/ritonavir, efavirenz, and tenofovir with the HCV protease inhibitor faldaprevir in healthy volunteers
|
|
|
Reported by Jules Levin
20th Conference on Retroviruses and Opportunistic Infections, March 3Ð6, 2013
John P Sabo,1 Jens Kort,1 Manuel Haschke,2
Charles Ballow,3 Birgit Girlich,4 Ulrich Feifel,5
Benjamin Lang,6 Michael Schobelock,1 Mabrouk Elgadi7
1Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT, USA; 2University Hospital Basel, Basel, Switzerland; 3Buffalo Clinical Research Center, Buffalo, NY, USA; 4Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland; 5Boehringer Ingelheim Pharmaceuticals GmbH & Co KG, Ingelheim, Germany;
6Boehringer Ingelheim Pharmaceuticals GmbH & Co KG, Biberach, Germany;
7Boehringer Ingelheim (Canada) Ltd, Burlington, Ontario, Canada
![CROI1.gif](../images/030413/030413-3/CROI1.gif)
![CROI2.gif](../images/030413/030413-3/CROI2.gif)
![CROI3.gif](../images/030413/030413-3/CROI3.gif)
![CROI4.gif](../images/030413/030413-3/CROI4.gif)
![CROI5.gif](../images/030413/030413-3/CROI5.gif)
![CROI6.gif](../images/030413/030413-3/CROI6.gif)
![CROI7.gif](../images/030413/030413-3/CROI7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|